Suppr超能文献

人类乳腺癌驱动因素、脆弱性和抗性的功能基因组图谱

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.

作者信息

Marcotte Richard, Sayad Azin, Brown Kevin R, Sanchez-Garcia Felix, Reimand Jüri, Haider Maliha, Virtanen Carl, Bradner James E, Bader Gary D, Mills Gordon B, Pe'er Dana, Moffat Jason, Neel Benjamin G

机构信息

Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.

The Donnelly Centre, University of Toronto, ON M5S 3E1, Canada.

出版信息

Cell. 2016 Jan 14;164(1-2):293-309. doi: 10.1016/j.cell.2015.11.062.

Abstract

Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations and point mutations. Still, identifying causal variants and emergent vulnerabilities that arise as a consequence of genetic alterations remain major challenges. We performed whole-genome small hairpin RNA (shRNA) "dropout screens" on 77 breast cancer cell lines. Using a hierarchical linear regression algorithm to score our screen results and integrate them with accompanying detailed genetic and proteomic information, we identify vulnerabilities in breast cancer, including candidate "drivers," and reveal general functional genomic properties of cancer cells. Comparisons of gene essentiality with drug sensitivity data suggest potential resistance mechanisms, effects of existing anti-cancer drugs, and opportunities for combination therapy. Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors.

摘要

大规模基因组研究已在乳腺癌中鉴定出多种体细胞畸变,包括拷贝数改变和点突变。然而,识别由基因改变导致的因果变异和新出现的脆弱性仍然是重大挑战。我们对77个乳腺癌细胞系进行了全基因组小发夹RNA(shRNA)“敲除筛选”。使用分层线性回归算法对筛选结果进行评分,并将其与附带的详细遗传和蛋白质组学信息整合,我们识别出乳腺癌中的脆弱性,包括候选“驱动因素”,并揭示癌细胞的一般功能基因组特性。基因必需性与药物敏感性数据的比较表明了潜在的耐药机制、现有抗癌药物的作用以及联合治疗的机会。最后,我们通过将BRD4鉴定为管腔型乳腺癌的潜在靶点以及将PIK3CA突变鉴定为BET抑制剂的耐药决定因素,证明了这个大型数据集的实用性。

相似文献

1
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
Cell. 2016 Jan 14;164(1-2):293-309. doi: 10.1016/j.cell.2015.11.062.
4
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Breast Cancer Res. 2005;7(5):R609-16. doi: 10.1186/bcr1262. Epub 2005 May 31.
5
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
Cancer Res. 2008 Jul 1;68(13):5380-9. doi: 10.1158/0008-5472.CAN-08-0234.
6
Integration of genomic data enables selective discovery of breast cancer drivers.
Cell. 2014 Dec 4;159(6):1461-75. doi: 10.1016/j.cell.2014.10.048. Epub 2014 Nov 26.
9
An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.
Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5.

引用本文的文献

1
Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma.
Oncogene. 2025 Sep 6. doi: 10.1038/s41388-025-03562-2.
4
Functional Pathway Inference Analysis (FPIA).
Methods Mol Biol. 2025;2932:203-229. doi: 10.1007/978-1-0716-4566-6_11.
5
CRISPR screening approaches in breast cancer research.
Cancer Metastasis Rev. 2025 Jul 12;44(3):59. doi: 10.1007/s10555-025-10275-1.
6
Enter sandman: how to tackle dormant breast cancer cells.
Med Oncol. 2025 Jun 18;42(7):271. doi: 10.1007/s12032-025-02833-y.
7
Metabolic Effects of the Cancer Metastasis Modulator MEMO1.
Metabolites. 2025 Apr 17;15(4):277. doi: 10.3390/metabo15040277.
10
PHLPP2 is a pseudophosphatase that lost activity in the metazoan ancestor.
Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2417218122. doi: 10.1073/pnas.2417218122. Epub 2025 Apr 1.

本文引用的文献

1
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Nature. 2015 Sep 17;525(7569):384-8. doi: 10.1038/nature14985. Epub 2015 Sep 2.
2
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Cancer Cell. 2015 Jun 8;27(6):837-51. doi: 10.1016/j.ccell.2015.05.006.
3
Therapeutic targets of triple-negative breast cancer: a review.
Br J Pharmacol. 2015 Sep;172(17):4228-37. doi: 10.1111/bph.13211. Epub 2015 Jul 30.
5
ATM kinase sustains HER2 tumorigenicity in breast cancer.
Nat Commun. 2015 Apr 16;6:6886. doi: 10.1038/ncomms7886.
6
Palbociclib: first global approval.
Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9.
7
Integration of genomic data enables selective discovery of breast cancer drivers.
Cell. 2014 Dec 4;159(6):1461-75. doi: 10.1016/j.cell.2014.10.048. Epub 2014 Nov 26.
8
p38δ MAPK: Emerging Roles of a Neglected Isoform.
Int J Cell Biol. 2014;2014:272689. doi: 10.1155/2014/272689. Epub 2014 Sep 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验